CorMedix (CRMD) Equity Average (2011 - 2025)

CorMedix has disclosed Equity Average across 13 years of filings, most recently posting $389.7 million for Q4 2025.

• Equity Average for Q4 2025 came in at $389.7 million, up 443.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $389.7 million (up 443.66% YoY), and the FY2025 annual result was $245.0 million, up 216.52% from the prior year.
• Equity Average came in at $389.7 million for Q4 2025 at CorMedix, up from $297.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $389.7 million in Q4 2025 to a low of $51.5 million in Q2 2023.
• The 5-year median for Equity Average is $65.1 million (2021), against an average of $98.0 million.
• Across the five-year window, Equity Average slumped 54.42% in 2021 and surged 467.0% in 2025, its largest moves.
• CorMedix's Equity Average stood at $66.1 million in 2021, then slipped by 15.72% to $55.7 million in 2022, then surged by 37.69% to $76.7 million in 2023, then fell by 6.5% to $71.7 million in 2024, then surged by 443.66% to $389.7 million in 2025.
• The last three Equity Average figures came in at $389.7 million (Q4 2025), $297.4 million (Q3 2025), and $167.8 million (Q2 2025), per Business Quant data.